Anti-idiotypic Patents (Class 530/387.2)
-
Publication number: 20090087427Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.Type: ApplicationFiled: December 8, 2006Publication date: April 2, 2009Inventors: Bjorn Frendeus, Roland Carlsson, Anne-Christine Carlsson
-
Publication number: 20090074799Abstract: Antibodies to novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in kidneys, pancreas, prostate, adrenal cortex and nervous tissue. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.Type: ApplicationFiled: June 9, 2008Publication date: March 19, 2009Inventors: Si Lok, Choon J. Kho, Anna C. Jelmberg, Robyn L. Adams, Theodore E. Whitmore, Theresa M. Farrah
-
Publication number: 20090075297Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.Type: ApplicationFiled: August 26, 2008Publication date: March 19, 2009Inventors: MARVIN BAYNE, Tanaz Hashemi, Chaogang He, Suke Wang
-
Publication number: 20090068172Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.Type: ApplicationFiled: August 27, 2008Publication date: March 12, 2009Inventors: Zehra Kaymakcalan, Limin Xiong
-
Publication number: 20090068109Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: November 19, 2007Publication date: March 12, 2009Inventors: Anuk Das, Raymond Sweet, Ping Tsui, Michael Bardroff
-
Publication number: 20090053294Abstract: Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.Type: ApplicationFiled: October 31, 2006Publication date: February 26, 2009Inventor: Patrick T. Prendergast
-
Publication number: 20090041660Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.Type: ApplicationFiled: September 5, 2008Publication date: February 12, 2009Inventor: Cohava Gelber
-
Publication number: 20090035316Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.Type: ApplicationFiled: September 5, 2008Publication date: February 5, 2009Inventor: Cohava Gelber
-
Publication number: 20090010924Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: ApplicationFiled: March 21, 2008Publication date: January 8, 2009Applicant: GENENTECH, INC.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Publication number: 20090004237Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: ApplicationFiled: June 27, 2008Publication date: January 1, 2009Applicant: AMGEN, INC.Inventors: Gary M. Fox, John K. Sullivan, Paige Holst, Steven Kiyoshi Yoshinaga
-
Publication number: 20080305038Abstract: The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to the cargo moiety to act as a carrier, particularly for efficient intracellular and/or intranuclear delivery of drugs, nano-or macromolecular structures, etc. The novel conjugate molecules are provided for the manufacture of a medicament for gene therapy, apoptosis, or for the treatment of diseases such as cancer, autoimmune diseases or infectious diseases.Type: ApplicationFiled: February 15, 2006Publication date: December 11, 2008Applicants: LUDWIG-MAXIMILIANS-UNIVERSITÄT, TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Joseph Rosenecker, Carsten Rudolph, Christian Plank, Markus Elfinger
-
Publication number: 20080274102Abstract: An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is provided.Type: ApplicationFiled: October 5, 2004Publication date: November 6, 2008Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTDInventors: David Wallach, Parameswaran Ramakrishnan
-
Patent number: 7446095Abstract: The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These sequences are needed in the same molecule for causing a wide range of biological activities. The peptides can be utilized to suppress apoptotic pathways by inhibiting the cytochrome c-mediated caspase activation. Thus, the peptides can be used to inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorders and immunodeficiency syndrome induced by viral infection, or to diminish side cytotoxic effects after chemotherapy and radiation therapy.Type: GrantFiled: October 7, 2003Date of Patent: November 4, 2008Inventors: Elena Ivanovna Dudich, Lidia Nikolaevna Semenkova, Igor Vyacheslavovitch Dudich, Edvward Borisovitch Tatulov, Dimitry Lvovicth Zubov, Timo Kalevi Korpela
-
Publication number: 20080268459Abstract: This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention.Type: ApplicationFiled: August 10, 2004Publication date: October 30, 2008Inventors: Zhanqi Liu, Andrew Mark Scott, Fiona E. Smyth
-
Publication number: 20080267988Abstract: Optimization and validation of a serum test confirms symptomatic autoimmune diseases e.g. multiple sclerosis (MS) or rheumatoid arthritis, and identifies early, silent diseases. The methods involve testing of subject sera for the presence of epitope-specific serum IgE and also non-IgE antibodies. The tests are immunoassays wherein serum autoantibodies complex with peptides structurally mimicking humoral, autoimmune epitopes on, for example, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) for MS. Each peptide: (1) is 5-6 amino acids long; (2) structurally and functionally mimics the surface region of its parent protein; and (3) offers a correct fit for the antigen binding site of a single specific autoantibody. Relapse prediction tests and therapies employ the peptides.Type: ApplicationFiled: April 11, 2008Publication date: October 30, 2008Applicant: Enteron Limited PartnershipInventor: Emanuel Calenoff
-
Patent number: 7442774Abstract: An antibody is provided which specifically recognizes and binds to INGAP protein. The antibody is used in competitive binding assays for quantitation of INGAP in biological samples. The assay can be performed on a solid support or in a suspension.Type: GrantFiled: October 6, 2005Date of Patent: October 28, 2008Assignee: GMP Endotherapeutics, Inc.Inventors: Aaron I. Vinik, David A. Taylor-Fishwick
-
Publication number: 20080260641Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: April 20, 2005Publication date: October 23, 2008Inventors: Jessica Teeling, Martin Glennie, Paul Parren, Arnout F. Gerritsen, Sigrid Ruuls, Yvo Graus, Jan van de Winkel
-
Patent number: 7435549Abstract: The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further relates to a kit comprising components such as panels of recombinant vectors of bacterial libraries transfected with a panel of recombinant vectors which is useful in carrying out the method of the invention. Furthermore, binding site domains and fusion proteins obtainable by the method of the invention as well as antibody-like molecules comprising such domains and proteins are described. Furthermore, pharmaceutical and diagnostic compositions containing the above-described fusion proteins and polypeptides are provided.Type: GrantFiled: November 16, 1998Date of Patent: October 14, 2008Assignee: Micromet AGInventors: Peter Kufer, Tobias Raum, Katrin Borschert, Florian Zettl, Ralf Lutterbuse
-
Patent number: 7435800Abstract: Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.Type: GrantFiled: March 2, 2006Date of Patent: October 14, 2008Assignee: Chi-Mei Medical CenterInventor: Ming-Shi Chang
-
Patent number: 7431925Abstract: Methods using internal image antibodies for photodiagnosis and/or phototherapy. The internal image antibodies are conjugated with a photoactive molecule such as a dye or photosensitizer, to target specific regions, such as biological receptors. The photoactive molecules are then activated for diagnosis or therapy. Advantageously, the internal image antibody is specific for a biological receptor, but does not require isolation of the receptor to prepare the antibody, and provides the desired specificity and selectivity for targeted diagnosis or therapy.Type: GrantFiled: January 21, 2004Date of Patent: October 7, 2008Assignee: Mallinckrodt, Inc.Inventors: Raghavan Rajagopalan, Joseph E. Bugaj, Samuel I. Achilefu, Richard B. Dorshow
-
Publication number: 20080241194Abstract: This invention concerns novel compositions and methods for for the protection of organs and cells from damage caused by activated lymphocytes, NK-cells and NK-like cells, more particularly compositions and methods for the protection of vascular endothelial cells from immune system-mediated damage.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Ernest G. Hope, Robert Negrin
-
Publication number: 20080241154Abstract: Novel TNF receptor polypeptides are disclosed, along with polynucleotides encoding the polypeptides and uses thereof.Type: ApplicationFiled: November 28, 2007Publication date: October 2, 2008Applicant: AMGEN INC.Inventor: Chris Saris
-
Publication number: 20080241138Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.Type: ApplicationFiled: March 26, 2008Publication date: October 2, 2008Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
-
Patent number: 7427664Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 7, 2002Date of Patent: September 23, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Publication number: 20080213831Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor18.Type: ApplicationFiled: June 19, 2007Publication date: September 4, 2008Inventors: Scott R. Presnell, Rolf E. Kuestner, Zeren Gao
-
Patent number: 7413736Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.Type: GrantFiled: July 25, 2007Date of Patent: August 19, 2008Assignee: Immunomedics, Inc.Inventors: Shui-on Leung, Michele J. Losman, Hans Hansen
-
Patent number: 7411045Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: GrantFiled: November 19, 2002Date of Patent: August 12, 2008Assignee: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Publication number: 20080187528Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.Type: ApplicationFiled: November 15, 2007Publication date: August 7, 2008Applicant: Functional Genetics, Inc.Inventors: Limin Li, Michael Kinch, Michael Goldblatt
-
Publication number: 20080176268Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).Type: ApplicationFiled: October 31, 2007Publication date: July 24, 2008Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 7399469Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.Type: GrantFiled: March 25, 2005Date of Patent: July 15, 2008Assignee: PDL BioPharma, Inc.Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
-
Publication number: 20080160015Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.Type: ApplicationFiled: February 26, 2007Publication date: July 3, 2008Inventors: Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
-
Publication number: 20080161540Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: December 10, 2007Publication date: July 3, 2008Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
-
Publication number: 20080118939Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.Type: ApplicationFiled: November 16, 2007Publication date: May 22, 2008Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
-
Patent number: 7365162Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.Type: GrantFiled: August 26, 2005Date of Patent: April 29, 2008Assignee: University of Georgia Research Foundation, Inc.Inventor: Elliot Altman
-
Patent number: 7300651Abstract: The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals.Type: GrantFiled: April 6, 2004Date of Patent: November 27, 2007Assignee: University of Kentucky Research FoundationInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 7262062Abstract: As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis.Type: GrantFiled: June 25, 2004Date of Patent: August 28, 2007Assignee: Keio UniversityInventor: Masataka Kuwana
-
Patent number: 7252954Abstract: The present invention relates generally to sets of digital antibodies directed against short epitopes, and use thereof in methods for protein analysis.Type: GrantFiled: October 15, 2003Date of Patent: August 7, 2007Assignee: Abmetrix, Inc.Inventors: Jianfu Jeffrey Wang, Weixing Helen Hu
-
Patent number: 7183384Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen with an apparent molecular weight of 150 kd and polynucleotides encoding the antigen and the CDR regions of the antibody are Also disclosed are methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: GrantFiled: March 8, 2004Date of Patent: February 27, 2007Assignee: A & G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hu
-
Patent number: 7151166Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: February 27, 2004Date of Patent: December 19, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman
-
Patent number: 7148330Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 30, 2001Date of Patent: December 12, 2006Assignee: Schering CorporationInventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
-
Patent number: 7119175Abstract: A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: December 29, 2003Date of Patent: October 10, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
-
Patent number: 7115715Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).Type: GrantFiled: September 27, 2001Date of Patent: October 3, 2006Assignee: Institute of Virology Slovak Academy of SciencesInventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 7105491Abstract: This invention provides nucleic acid sequences and characterization of the gene cluster responsible for the biosynthesis of the enediyne C-1027 (produced by Streptomyces globisporus). Methods are provided for the biosynthesis of enediynes, enediyne analogs and other biological molecules. This invention also provides enediyne and enediyne analogs biosynthesized by manipulation of the C-1027 gene pathway.Type: GrantFiled: November 12, 2002Date of Patent: September 12, 2006Assignee: Wisconsin Alumni Research Foundation (WARF)Inventors: Ben Shen, Wen Liu
-
Patent number: 7101674Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: GrantFiled: July 2, 2001Date of Patent: September 5, 2006Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
-
Patent number: 7090842Abstract: This invention provides compositions derived from the sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 3H1 and methods for using these compositions.Type: GrantFiled: December 28, 1995Date of Patent: August 15, 2006Assignee: Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon
-
Patent number: 7083943Abstract: The present invention provides a monoclonal and-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 inducts an Immunological response to HMFG in mice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.Type: GrantFiled: December 19, 1996Date of Patent: August 1, 2006Inventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 7078175Abstract: Disclosed is the isolation and characterization of EI24, a gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples.Type: GrantFiled: March 12, 2003Date of Patent: July 18, 2006Assignee: Immunogen, Inc.Inventors: Sophie M. Lehar, Braydon C. Guild
-
Patent number: 7041288Abstract: Antibodies and antibody fragments which are anti-idiotypic to an antibody that interferes with the binding of the C?3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti-idiotypic to BSW17 (BSW17-mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE-mediated diseases.Type: GrantFiled: October 10, 2001Date of Patent: May 9, 2006Assignee: Novartis AGInventors: Franz Kricek, Beda Stadler, Monique Vogel
-
Patent number: 7026446Abstract: The invention relates to a chimeric antibody conjugate comprising an antigen binding region of a non-human antibody and an immunoglobulin constant region which comprises at least one CH domain or epitope thereof, with the proviso that the constant region is not a naturally occurring FC fragment. A bifunctional molecule for use in labelling an antibody derived from a first species, the bifunctional molecule comprising a binding region which binds to the antibody of the first species or to one or more groups provided thereon, and a constant region derived from an antibody of a second species, the constant region comprising at least one CH domain or an epitope thereof. The present invention relates to bifunctional molecules and complexes which are useful as positive control reagents in antibody based diagnostic tests. The present invention also relates to polynucleotides encoding these bifunctional molecules, and to diagnostic assays involving the use of these molecules.Type: GrantFiled: December 24, 1998Date of Patent: April 11, 2006Assignee: Diatech Pty Ltd.Inventors: John Leslie Atwell, Peter Leonard Devine, Gregory Coia, Alexander Andrew Kortt, Gillian Wendy Perry, Peter Gregory Bundesen
-
Patent number: 6949244Abstract: The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.Type: GrantFiled: December 13, 1996Date of Patent: September 27, 2005Assignee: The Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee